Your session is about to expire
← Back to Search
Sleep Self-Management for Type 1 Diabetes (SLEEPT1D Trial)
SLEEPT1D Trial Summary
This trial is testing whether a sleep self-management intervention can help young adults with type 1 diabetes improve their sleep and glycemic control.
SLEEPT1D Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSLEEPT1D Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SLEEPT1D Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Diabetes Self-Management Education
- Group 2: Sleep Self-Management
Frequently Asked Questions
What is the maximum participant rate for this clinical research?
"Affirmative. The information available on clinicaltrials.gov indicates that the research study is still recruiting, having first been posted on April 29th 2022 and most recently updated May 17th of the same year. 48 participants will be admitted to this single site trial."
Is eligibility restricted to persons over the age of 75 for this clinical experiment?
"To be included in this medical trial, applicants must have aged between 18 and 25 years old. For individuals under 18 years of age or over 65 there are 218 and 925 respective clinical trials currently available."
What criteria are being utilized to select individuals for this medical research?
"The requirements to enroll are that patients must be 18-25 years old and have a diagnosis of diabetes mellitus. This study is only admitting 48 individuals total."
Is there still room to participate in this investigation?
"Correct. The clinicaltrials.gov website reveals that this research endeavor, which was first published on April 29th 2022, is actively recruiting volunteers. 48 individuals are needed to be enlisted from a single site."
To what end is this scientific experiment striving?
"The core purpose of this trial, beginning at the baseline (T0) through 90 days post-intervention (T3), is to assess repeated measurements. Secondary goals involve utilizing PROMIS v1.0 and examining any alterations in general distress levels; additionally, a paper-based Trail Making Test for both parts A & B will be administered with an aim to gauge executive function changes; finally, a 10 minute Psychomotor Vigilance Test on PVT 192 device intends to examine shifts in corresponding scores from these tests - lower values signalling improvement."
Share this study with friends
Copy Link
Messenger